Kidney cancer study shows improved outcomes for patients with advanced disease when treated with belzutifan over everolimus
Dana-Farber Cancer InstituteBelzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial.